Fmr LLC Boosts Holdings in Outset Medical, Inc. (NASDAQ:OM)

Fmr LLC grew its position in shares of Outset Medical, Inc. (NASDAQ:OM) by 0.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,295,558 shares of the company’s stock after purchasing an additional 49,376 shares during the period. Fmr LLC owned approximately 14.82% of Outset Medical worth $134,238,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in OM. US Bancorp DE raised its stake in shares of Outset Medical by 286.7% during the first quarter. US Bancorp DE now owns 2,711 shares of the company’s stock valued at $123,000 after purchasing an additional 2,010 shares during the period. AlphaCrest Capital Management LLC bought a new stake in shares of Outset Medical in the first quarter worth $278,000. MetLife Investment Management LLC increased its stake in shares of Outset Medical by 53.4% in the first quarter. MetLife Investment Management LLC now owns 26,064 shares of the company’s stock worth $1,183,000 after buying an additional 9,070 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Outset Medical by 4.2% in the first quarter. Rhumbline Advisers now owns 49,144 shares of the company’s stock worth $2,231,000 after buying an additional 2,000 shares during the last quarter. Finally, Lord Abbett & CO. LLC increased its stake in shares of Outset Medical by 1.8% in the first quarter. Lord Abbett & CO. LLC now owns 222,923 shares of the company’s stock worth $10,121,000 after buying an additional 4,042 shares during the last quarter.

Outset Medical Stock Up 2.0 %

OM stock opened at $13.88 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 6.34 and a quick ratio of 5.43. Outset Medical, Inc. has a 1-year low of $11.41 and a 1-year high of $30.55. The firm has a fifty day moving average price of $17.80 and a two-hundred day moving average price of $19.71. The firm has a market cap of $691.09 million, a price-to-earnings ratio of -3.95 and a beta of 1.44.

Outset Medical (NASDAQ:OM) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Outset Medical had a negative return on equity of 73.66% and a negative net margin of 131.69%. The firm had revenue of $36.04 million for the quarter, compared to the consensus estimate of $35.18 million. Research analysts predict that Outset Medical, Inc. will post -3.42 EPS for the current year.

Wall Street Analyst Weigh In

OM has been the subject of a number of research analyst reports. Morgan Stanley dropped their price target on shares of Outset Medical from $22.00 to $19.00 and set an “equal weight” rating for the company in a research note on Thursday, August 24th. CL King initiated coverage on shares of Outset Medical in a research note on Thursday, August 17th. They issued a “neutral” rating for the company. Royal Bank of Canada restated an “outperform” rating and issued a $29.00 price target on shares of Outset Medical in a research note on Thursday, August 17th. Finally, 888 reiterated a “maintains” rating on shares of Outset Medical in a research note on Wednesday, May 31st. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $24.20.

Insider Buying and Selling at Outset Medical

In related news, General Counsel John L. Brottem sold 1,414 shares of the stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $21.97, for a total value of $31,065.58. Following the completion of the transaction, the general counsel now directly owns 58,945 shares of the company’s stock, valued at approximately $1,295,021.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, General Counsel John L. Brottem sold 1,414 shares of the stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $21.97, for a total value of $31,065.58. Following the completion of the transaction, the general counsel now directly owns 58,945 shares of the company’s stock, valued at approximately $1,295,021.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Leslie Trigg sold 20,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $20.90, for a total value of $418,000.00. Following the completion of the transaction, the chief executive officer now directly owns 409,489 shares of the company’s stock, valued at $8,558,320.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,819 shares of company stock worth $498,849. 4.00% of the stock is owned by company insiders.

Outset Medical Profile

Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.